| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -2222.45% | -1542.63% | -299.86% | -320.23% | -388.56% | -407.47% | -943.14% | -1415.44% | -1025.94% | -726.10% | -1142.82% | — |
| EBITDA Margin | -2028.33% | -1403.52% | -271.09% | -305.95% | -378.08% | -397.65% | -922.60% | -1390.04% | -1002.29% | -706.09% | -1114.56% | — |
| Net Margin | -2051.08% | -1366.46% | -253.30% | -292.55% | -379.89% | -551.59% | -919.00% | -1405.02% | -1046.08% | -760.15% | -1233.73% | — |
| Current Ratio | 5.79 | 7.58 | 8.48 | 4.40 | 7.79 | 5.78 | 8.17 | 7.53 | 9.29 | 6.14 | 4.88 | 10.89 |
| Quick Ratio | 5.79 | 7.58 | 8.48 | 4.40 | 7.79 | 5.78 | 8.17 | 7.53 | 9.29 | 6.14 | 4.88 | 10.89 |
| Debt / Equity | 0.35 | 0.24 | 0.26 | 0.21 | 0.16 | 0.24 | — | 0.09 | 0.19 | 0.15 | 0.48 | 0.69 |
| ROE | -65.79% | -58.44% | -43.68% | -58.21% | -31.25% | -45.10% | -40.10% | -41.50% | -55.65% | -45.74% | -78.85% | -91.33% |
| ROA | -42.74% | -42.27% | -31.79% | -39.93% | -23.02% | -27.86% | -32.47% | -31.26% | -40.79% | -35.21% | -44.13% | -50.55% |
| Asset Turnover | 0.02 | 0.03 | 0.13 | 0.14 | 0.06 | 0.05 | 0.04 | 0.02 | 0.04 | 0.05 | 0.04 | — |
| Book Value / Share | 1.74 | 2.80 | 3.74 | 5.00 | 7.16 | 4.67 | 3.59 | 2.86 | 1.84 | 2.30 | 1.49 | — |
Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies using induced pluripotent stem cell (iPSC) technology to treat cancer and autoimmune diseases. The company's pipeline includes FT819, an off-the-shelf CAR T-cell candidate for systemic lupus erythematosus and other autoimmune conditions, which has demonstrated rapid B-cell depletion and durable clinical responses in Phase 1 studies with reduced or eliminated conditioning chemotherapy requirements. Additional programs include FT825 and FT836 for various solid tumors and hematologic cancers, and FT522 for B-cell lymphoma. Fate Therapeutics' approach focuses on multiplexed-engineered cell products designed to overcome manufacturing and development limitations inherent to traditional cell therapies. The company emphasizes the potential for same-day discharge and outpatient administration of its therapies, aiming to make cell therapy delivery more routine and accessible while addressing significant unmet medical needs in oncology and immunology.